ANTXR1/TEM8 Antibody recognizes endogenous levels of total ANTXR1/TEM8 protein.

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg557 of human ANTXR1/TEM8 protein. Antibodies are purified by peptide affinity chromatography.

ANTXR1 (Anthrax toxin receptor 1, TEM8, tumor endothelial marker 8) is a protein biomarker induced in tumor-associated endothelia and acts as a cell surface receptor for the anthrax toxin and the oncolytic Seneca Valley Virus (1-3). The protein is a type I transmembrane glycoprotein that is expressed on the epithelial cell surface of skin, lung, and intestine tissues as a docking site for toxin/virus binding and endocytosis, and in tumor endothelial cells for tumor-associated vascular development (4). ANTXR1 interacts with type I and type VI collagens in the extracellular matrix, and with actin cytoskeleton in the cytoplasm to promote tumor-associated endothelial cell adhesion, migration, and spreading during angiogenesis (4-6). Aberrant high expression of ANTXR1 has been found in various cancer types including metastatic breast cancer cells, pancreatic cancer stem cells, etc. (7-9); there the protein promotes tumor proliferation, growth, and invasion. Because of its specific high expression in tumors and to their surrounding vasculature, ANTXR1 has been proposed as a target for CAR T cell therapy for cancer treatment (10,11).